Literature DB >> 32726837

Pneumonic versus Nonpneumonic Exacerbations of Chronic Obstructive Pulmonary Disease.

Ernesto Crisafulli1,2, Alessandra Manco3, Miquel Ferrer4, Arturo Huerta4, Claudio Micheletto5, Domenico Girelli2, Enrico Clini6, Antoni Torres4.   

Abstract

Patients with chronic obstructive pulmonary disease (COPD) often suffer acute exacerbations (AECOPD) and community-acquired pneumonia (CAP), named nonpneumonic and pneumonic exacerbations of COPD, respectively. Abnormal host defense mechanisms may play a role in the specificity of the systemic inflammatory response. Given the association of this aspect to some biomarkers at admission (e.g., C-reactive protein), it can be used to help to discriminate AECOPD and CAP, especially in cases with doubtful infiltrates and advanced lung impairment. Fever, sputum purulence, chills, and pleuritic pain are typical clinical features of CAP in a patient with COPD, whereas isolated dyspnea at admission has been reported to predict AECOPD. Although CAP may have a worse outcome in terms of mortality (in hospital and short term), length of hospitalization, and early readmission rates, this has only been confirmed in a few prospective studies. There is a lack of methodologically sound research confirming the impact of severe AECOPD and COPD + CAP. Here, we review studies reporting head-to-head comparisons between AECOPD and CAP + COPD in hospitalized patients. We focus on the epidemiology, risk factors, systemic inflammatory response, clinical and microbiological characteristics, outcomes, and treatment approaches. Finally, we briefly discuss some proposals on how we should orient research in the future. Thieme. All rights reserved.

Entities:  

Year:  2020        PMID: 32726837     DOI: 10.1055/s-0040-1702196

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  1 in total

1.  Etiology of Emergency Visit and In-Hospital Outcomes of Patients with COPD.

Authors:  Xueyang Zhang; Qingtao Zhou; Shengfeng Wang; Qingbian Ma; Yongchang Sun
Journal:  Emerg Med Int       Date:  2022-08-29       Impact factor: 1.621

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.